Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma

The role of promoter methylation in the inactivation of E‑cadherin (CDH1) in salivary carcinoma ex pleomorphic adenoma (CXPA) is unknown. The objective of this study was to determine the role and potential clinical implications of CDH1 promoter methylation in salivary CXPA. The CDH1 promoter methyla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of oncology 2018-02, Vol.52 (2), p.496-504
Hauptverfasser: Xia, Liang, Hu, Yuhua, Gu, Ting, Wang, Lizhen, Tian, Zhen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 504
container_issue 2
container_start_page 496
container_title International journal of oncology
container_volume 52
creator Xia, Liang
Hu, Yuhua
Gu, Ting
Wang, Lizhen
Tian, Zhen
description The role of promoter methylation in the inactivation of E‑cadherin (CDH1) in salivary carcinoma ex pleomorphic adenoma (CXPA) is unknown. The objective of this study was to determine the role and potential clinical implications of CDH1 promoter methylation in salivary CXPA. The CDH1 promoter methylation status was determined by bisulfite sequencing PCR in 37 primary CXPA tissues and 2 CXPA cell lines. E‑cadherin expression levels were determined by immunohistochemical analysis of each tumor. E‑cadherin protein levels and CDH1 mRNA levels were examined by immunoblotting and quantitative real-time PCR, respectively, in 2 CXPA cell lines. Cells were treated with 5‑Aza-dC or TGF‑β1 to test the influence of promoter methylation on CDH1 mRNA and protein expression. Associations between CDH1 molecular alterations and patients' clinicopathologic characteristics and prognosis were statistically evaluated. CDH1 promoter hypermethylation was detected in 21 of 37 tumors (56.76%). Of these 37 tumors, 13 tumors (35.14%) showed low E‑cadherin expression. Tumors that had CDH1 promoter methylation had a histological tendency toward luminal differentiation (P=0.004), high tumor grade (P=0.005), high T stage (P=0.024) and high TNM stage (P=0.038) compared with tumors that did not. The two CXPA cell lines exhibited an inverse relationship between CDH1 promoter methylation status and CDH1 mRNA and protein expression. Treatment of the hypermethylated cell line with 5‑Aza-dC restored CDH1 mRNA and E‑cadherin protein expression. The induction of hypermethylation by TGF‑β1 resulted in the repression of CDH1 mRNA and protein expression. CDH1 is commonly silenced in CXPA through promoter methylation. CDH1 methylation is closely related to tumor cell differentiation, histological grade, lymph node metastasis and advanced TNM stage, indicating that CDH1 methylation may play a role in the initiation and progression of CXPA.
doi_str_mv 10.3892/ijo.2017.4210
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1990442199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A525994212</galeid><sourcerecordid>A525994212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-b9cbefa5b077dcc99a7f442b3c78eeea0a5d2e7217bd8dfdf7f90257f6452ba43</originalsourceid><addsrcrecordid>eNptkcuKFTEQhoMozji6dCsBwV0fk3T35GQ5DOMFBnSh61CdVOwcOp02SYvHla_gK_okppnxMiBZVKr4qor6f0KecrZr90q89Ie4E4zLXSc4u0dOuVS8EZ1o79c_46o571p1Qh7lfGBM9D3jD8mJUIJJtu9Oybf3KYZYMNHxuGAKWMbjBMXHmQY4UhPnkvywFqQl0quf338YsCMmP9OES8KcN7JmZUQ6rgFmmmHyXyDVXkjGzzEAxa90mbDuScvoDQWLW_kxeeBgyvjkNp6Rj6-uPly-aa7fvX57eXHdmF50pRmUGdBBPzAprTFKgXRdJ4bWyD0iAoPeCpSCy8HurbNOOlUPle6868UAXXtGnt_MXVL8vGIu-hDXNNeVmivF6qwa_lKfYELtZxdLAhN8NvqiF71SFROV2v2Hqs9i8FUsdL7W7zS8-KdhRJjKmOO0bgrnu2BzA5oUc07o9JJ8qDpqzvTmtK5O681pvTld-We3V61DQPuH_m1t-wvtFaZ-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1990442199</pqid></control><display><type>article</type><title>Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Xia, Liang ; Hu, Yuhua ; Gu, Ting ; Wang, Lizhen ; Tian, Zhen</creator><creatorcontrib>Xia, Liang ; Hu, Yuhua ; Gu, Ting ; Wang, Lizhen ; Tian, Zhen</creatorcontrib><description>The role of promoter methylation in the inactivation of E‑cadherin (CDH1) in salivary carcinoma ex pleomorphic adenoma (CXPA) is unknown. The objective of this study was to determine the role and potential clinical implications of CDH1 promoter methylation in salivary CXPA. The CDH1 promoter methylation status was determined by bisulfite sequencing PCR in 37 primary CXPA tissues and 2 CXPA cell lines. E‑cadherin expression levels were determined by immunohistochemical analysis of each tumor. E‑cadherin protein levels and CDH1 mRNA levels were examined by immunoblotting and quantitative real-time PCR, respectively, in 2 CXPA cell lines. Cells were treated with 5‑Aza-dC or TGF‑β1 to test the influence of promoter methylation on CDH1 mRNA and protein expression. Associations between CDH1 molecular alterations and patients' clinicopathologic characteristics and prognosis were statistically evaluated. CDH1 promoter hypermethylation was detected in 21 of 37 tumors (56.76%). Of these 37 tumors, 13 tumors (35.14%) showed low E‑cadherin expression. Tumors that had CDH1 promoter methylation had a histological tendency toward luminal differentiation (P=0.004), high tumor grade (P=0.005), high T stage (P=0.024) and high TNM stage (P=0.038) compared with tumors that did not. The two CXPA cell lines exhibited an inverse relationship between CDH1 promoter methylation status and CDH1 mRNA and protein expression. Treatment of the hypermethylated cell line with 5‑Aza-dC restored CDH1 mRNA and E‑cadherin protein expression. The induction of hypermethylation by TGF‑β1 resulted in the repression of CDH1 mRNA and protein expression. CDH1 is commonly silenced in CXPA through promoter methylation. CDH1 methylation is closely related to tumor cell differentiation, histological grade, lymph node metastasis and advanced TNM stage, indicating that CDH1 methylation may play a role in the initiation and progression of CXPA.</description><identifier>ISSN: 1019-6439</identifier><identifier>EISSN: 1791-2423</identifier><identifier>DOI: 10.3892/ijo.2017.4210</identifier><identifier>PMID: 29207084</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Adenoma ; Cadherins ; Cancer ; Care and treatment ; Cell adhesion &amp; migration ; Deoxyribonucleic acid ; Development and progression ; DNA ; DNA methylation ; Epigenetics ; Gene expression ; Genetic aspects ; Health aspects ; Lymphatic system ; Medical prognosis ; Oral cancer ; Polymerase chain reaction ; Promoters (Genetics) ; Protein expression ; Tumors</subject><ispartof>International journal of oncology, 2018-02, Vol.52 (2), p.496-504</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-b9cbefa5b077dcc99a7f442b3c78eeea0a5d2e7217bd8dfdf7f90257f6452ba43</citedby><cites>FETCH-LOGICAL-c524t-b9cbefa5b077dcc99a7f442b3c78eeea0a5d2e7217bd8dfdf7f90257f6452ba43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29207084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Hu, Yuhua</creatorcontrib><creatorcontrib>Gu, Ting</creatorcontrib><creatorcontrib>Wang, Lizhen</creatorcontrib><creatorcontrib>Tian, Zhen</creatorcontrib><title>Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma</title><title>International journal of oncology</title><addtitle>Int J Oncol</addtitle><description>The role of promoter methylation in the inactivation of E‑cadherin (CDH1) in salivary carcinoma ex pleomorphic adenoma (CXPA) is unknown. The objective of this study was to determine the role and potential clinical implications of CDH1 promoter methylation in salivary CXPA. The CDH1 promoter methylation status was determined by bisulfite sequencing PCR in 37 primary CXPA tissues and 2 CXPA cell lines. E‑cadherin expression levels were determined by immunohistochemical analysis of each tumor. E‑cadherin protein levels and CDH1 mRNA levels were examined by immunoblotting and quantitative real-time PCR, respectively, in 2 CXPA cell lines. Cells were treated with 5‑Aza-dC or TGF‑β1 to test the influence of promoter methylation on CDH1 mRNA and protein expression. Associations between CDH1 molecular alterations and patients' clinicopathologic characteristics and prognosis were statistically evaluated. CDH1 promoter hypermethylation was detected in 21 of 37 tumors (56.76%). Of these 37 tumors, 13 tumors (35.14%) showed low E‑cadherin expression. Tumors that had CDH1 promoter methylation had a histological tendency toward luminal differentiation (P=0.004), high tumor grade (P=0.005), high T stage (P=0.024) and high TNM stage (P=0.038) compared with tumors that did not. The two CXPA cell lines exhibited an inverse relationship between CDH1 promoter methylation status and CDH1 mRNA and protein expression. Treatment of the hypermethylated cell line with 5‑Aza-dC restored CDH1 mRNA and E‑cadherin protein expression. The induction of hypermethylation by TGF‑β1 resulted in the repression of CDH1 mRNA and protein expression. CDH1 is commonly silenced in CXPA through promoter methylation. CDH1 methylation is closely related to tumor cell differentiation, histological grade, lymph node metastasis and advanced TNM stage, indicating that CDH1 methylation may play a role in the initiation and progression of CXPA.</description><subject>Adenoma</subject><subject>Cadherins</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell adhesion &amp; migration</subject><subject>Deoxyribonucleic acid</subject><subject>Development and progression</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Epigenetics</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Oral cancer</subject><subject>Polymerase chain reaction</subject><subject>Promoters (Genetics)</subject><subject>Protein expression</subject><subject>Tumors</subject><issn>1019-6439</issn><issn>1791-2423</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkcuKFTEQhoMozji6dCsBwV0fk3T35GQ5DOMFBnSh61CdVOwcOp02SYvHla_gK_okppnxMiBZVKr4qor6f0KecrZr90q89Ie4E4zLXSc4u0dOuVS8EZ1o79c_46o571p1Qh7lfGBM9D3jD8mJUIJJtu9Oybf3KYZYMNHxuGAKWMbjBMXHmQY4UhPnkvywFqQl0quf338YsCMmP9OES8KcN7JmZUQ6rgFmmmHyXyDVXkjGzzEAxa90mbDuScvoDQWLW_kxeeBgyvjkNp6Rj6-uPly-aa7fvX57eXHdmF50pRmUGdBBPzAprTFKgXRdJ4bWyD0iAoPeCpSCy8HurbNOOlUPle6868UAXXtGnt_MXVL8vGIu-hDXNNeVmivF6qwa_lKfYELtZxdLAhN8NvqiF71SFROV2v2Hqs9i8FUsdL7W7zS8-KdhRJjKmOO0bgrnu2BzA5oUc07o9JJ8qDpqzvTmtK5O681pvTld-We3V61DQPuH_m1t-wvtFaZ-</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Xia, Liang</creator><creator>Hu, Yuhua</creator><creator>Gu, Ting</creator><creator>Wang, Lizhen</creator><creator>Tian, Zhen</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180201</creationdate><title>Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma</title><author>Xia, Liang ; Hu, Yuhua ; Gu, Ting ; Wang, Lizhen ; Tian, Zhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-b9cbefa5b077dcc99a7f442b3c78eeea0a5d2e7217bd8dfdf7f90257f6452ba43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenoma</topic><topic>Cadherins</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell adhesion &amp; migration</topic><topic>Deoxyribonucleic acid</topic><topic>Development and progression</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Epigenetics</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Oral cancer</topic><topic>Polymerase chain reaction</topic><topic>Promoters (Genetics)</topic><topic>Protein expression</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Xia, Liang</creatorcontrib><creatorcontrib>Hu, Yuhua</creatorcontrib><creatorcontrib>Gu, Ting</creatorcontrib><creatorcontrib>Wang, Lizhen</creatorcontrib><creatorcontrib>Tian, Zhen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xia, Liang</au><au>Hu, Yuhua</au><au>Gu, Ting</au><au>Wang, Lizhen</au><au>Tian, Zhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma</atitle><jtitle>International journal of oncology</jtitle><addtitle>Int J Oncol</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>52</volume><issue>2</issue><spage>496</spage><epage>504</epage><pages>496-504</pages><issn>1019-6439</issn><eissn>1791-2423</eissn><abstract>The role of promoter methylation in the inactivation of E‑cadherin (CDH1) in salivary carcinoma ex pleomorphic adenoma (CXPA) is unknown. The objective of this study was to determine the role and potential clinical implications of CDH1 promoter methylation in salivary CXPA. The CDH1 promoter methylation status was determined by bisulfite sequencing PCR in 37 primary CXPA tissues and 2 CXPA cell lines. E‑cadherin expression levels were determined by immunohistochemical analysis of each tumor. E‑cadherin protein levels and CDH1 mRNA levels were examined by immunoblotting and quantitative real-time PCR, respectively, in 2 CXPA cell lines. Cells were treated with 5‑Aza-dC or TGF‑β1 to test the influence of promoter methylation on CDH1 mRNA and protein expression. Associations between CDH1 molecular alterations and patients' clinicopathologic characteristics and prognosis were statistically evaluated. CDH1 promoter hypermethylation was detected in 21 of 37 tumors (56.76%). Of these 37 tumors, 13 tumors (35.14%) showed low E‑cadherin expression. Tumors that had CDH1 promoter methylation had a histological tendency toward luminal differentiation (P=0.004), high tumor grade (P=0.005), high T stage (P=0.024) and high TNM stage (P=0.038) compared with tumors that did not. The two CXPA cell lines exhibited an inverse relationship between CDH1 promoter methylation status and CDH1 mRNA and protein expression. Treatment of the hypermethylated cell line with 5‑Aza-dC restored CDH1 mRNA and E‑cadherin protein expression. The induction of hypermethylation by TGF‑β1 resulted in the repression of CDH1 mRNA and protein expression. CDH1 is commonly silenced in CXPA through promoter methylation. CDH1 methylation is closely related to tumor cell differentiation, histological grade, lymph node metastasis and advanced TNM stage, indicating that CDH1 methylation may play a role in the initiation and progression of CXPA.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>29207084</pmid><doi>10.3892/ijo.2017.4210</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1019-6439
ispartof International journal of oncology, 2018-02, Vol.52 (2), p.496-504
issn 1019-6439
1791-2423
language eng
recordid cdi_proquest_journals_1990442199
source Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adenoma
Cadherins
Cancer
Care and treatment
Cell adhesion & migration
Deoxyribonucleic acid
Development and progression
DNA
DNA methylation
Epigenetics
Gene expression
Genetic aspects
Health aspects
Lymphatic system
Medical prognosis
Oral cancer
Polymerase chain reaction
Promoters (Genetics)
Protein expression
Tumors
title Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A45%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Promoter%20hypermethylation%20may%20contribute%20to%20E%E2%80%91cadherin%20repression%20in%20the%20human%20salivary%20carcinoma%20ex%20pleomorphic%20adenoma&rft.jtitle=International%20journal%20of%20oncology&rft.au=Xia,%20Liang&rft.date=2018-02-01&rft.volume=52&rft.issue=2&rft.spage=496&rft.epage=504&rft.pages=496-504&rft.issn=1019-6439&rft.eissn=1791-2423&rft_id=info:doi/10.3892/ijo.2017.4210&rft_dat=%3Cgale_proqu%3EA525994212%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1990442199&rft_id=info:pmid/29207084&rft_galeid=A525994212&rfr_iscdi=true